ONC206 in Oncology

ONC206 is an imipridone that is a selective antagonist of dopamine receptor D2/3 (DRD2/3), exhibiting unique receptor pharmacology. It has demonstrated favorable drug characteristics, including efficacy against cancer in pre-clinical models with an exceptional safety profile.

For more information on ONC206, please refer to our Publications and to the ‘Our Science’ section of our website.

Development of ONC206

Given the therapeutic potential ONC206, Oncoceutics is working with leading researchers at the NIH on a timely clinical translation of ONC206 and has filed a pre-IND application with the FDA.

In 2018, Oncoceutics and Calvert Research announced that the two companies have entered into a product development and investment partnership agreement to further develop ONC206. Calvert Research will enlist the capabilities of its CRO affiliate, Calvert Laboratories, Inc. to conduct safety and pharmacology studies on ONC206.

Oncoceutics expects to complete all studies by the end of 2018, file the IND and begin first-in-human studies for ONC206 in 2019.

The United States Patent and Trademark Office (USPTO) has issued a patent providing the company with composition of matter protection for ONC206.